Interferon — Total Revenue
Biogen Interferon — Total Revenue increased by 0.8% to $227.50M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 0.5%, from $226.30M to $227.50M. Over 4 years (FY 2021 to FY 2025), Interferon — Total Revenue shows a downward trend with a -11.9% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase suggests sustained demand or successful retention of the patient base for legacy therapies, while a decrease indicates market erosion due to the adoption of newer, more convenient treatment alternatives.
Detailed definition
This metric represents the total gross revenue generated from the sale of interferon-based therapeutic products within t...
Peer comparison
Comparable to revenue segments for legacy neurology or immunology products at other large-cap biopharmaceutical companies facing patent cliffs or competitive displacement.
biib_segment_interferon_total_revenueHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $400.40M | $387.50M | $377.70M | $309.60M | $350.20M | $336.00M | $309.60M | $245.60M | $302.40M | $277.70M | $280.00M | $243.60M | $250.90M | $237.50M | $236.00M | $226.30M | $246.70M | $246.90M | $225.70M | $227.50M |
| QoQ Change | — | -3.2% | -2.5% | -18.0% | +13.1% | -4.1% | -7.9% | -20.7% | +23.1% | -8.2% | +0.8% | -13.0% | +3.0% | -5.3% | -0.6% | -4.1% | +9.0% | +0.1% | -8.6% | +0.8% |
| YoY Change | — | — | — | — | -12.5% | -13.3% | -18.0% | -20.7% | -13.6% | -17.4% | -9.6% | -0.8% | -17.0% | -14.5% | -15.7% | -7.1% | -1.7% | +4.0% | -4.4% | +0.5% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Biogen's interferon — total revenue?
- Biogen (BIIB) reported interferon — total revenue of $227.50M in Q1 2026.
- How has Biogen's interferon — total revenue changed year-over-year?
- Biogen's interferon — total revenue increased by 0.5% year-over-year, from $226.30M to $227.50M.
- What is the long-term trend for Biogen's interferon — total revenue?
- Over 4 years (2021 to 2025), Biogen's interferon — total revenue has grown at a -11.9% compound annual growth rate (CAGR), from $1.57B to $945.60M.
- What does interferon — total revenue mean?
- Total revenue generated from the sale of interferon-based multiple sclerosis drugs.